CERN, Geneva, Switzerland.
TERA Foundation, Novara, Italy.
Radiother Oncol. 2018 Jul;128(1):76-82. doi: 10.1016/j.radonc.2018.03.014. Epub 2018 Apr 3.
The European Network for Light Ion Hadron Therapy (ENLIGHT) was established in 2002 following various European particle therapy network initiatives during the 1980s and 1990s (e.g. EORTC task group, EULIMA/PIMMS accelerator design). ENLIGHT started its work on major topics related to hadron therapy (HT), such as patient selection, clinical trials, technology, radiobiology, imaging and health economics. It was initiated through CERN and ESTRO and dealt with various disciplines such as (medical) physics and engineering, radiation biology and radiation oncology. ENLIGHT was funded until 2005 through the EC FP5 programme. A regular annual meeting structure was started in 2002 and continues until today bringing together the various disciplines and projects and institutions in the field of HT at different European places for regular exchange of information on best practices and research and development. Starting in 2006 ENLIGHT coordination was continued through CERN in collaboration with ESTRO and other partners involved in HT. Major projects within the EC FP7 programme (2008-2014) were launched for R&D and transnational access (ULICE, ENVISION) and education and training networks (Marie Curie ITNs: PARTNER, ENTERVISION). These projects were instrumental for the strengthening of the field of hadron therapy. With the start of 4 European carbon ion and proton centres and the upcoming numerous European proton therapy centres, the future scope of ENLIGHT will focus on strengthening current and developing European particle therapy research, multidisciplinary education and training and general R&D in technology and biology with annual meetings and a continuously strong CERN support. Collaboration with the European Particle Therapy Network (EPTN) and other similar networks will be pursued.
欧洲轻离子强子治疗网络（ENLIGHT）成立于 2002 年，其前身为 20 世纪 80 年代和 90 年代的多个欧洲粒子治疗网络倡议，如 EORTC 工作组、EULIMA/PIMMS 加速器设计等。ENLIGHT 就强子治疗（HT）相关的主要主题开展工作，如患者选择、临床试验、技术、放射生物学、成像和健康经济学。该网络由 CERN 和 ESTRO 发起，涉及（医学）物理学和工程、辐射生物学和放射肿瘤学等多个学科。ENLIGHT 在 2005 年之前通过欧盟第五框架计划（FP5）获得资助。2002 年开始建立定期年会结构，一直延续至今，将 HT 领域的各个学科和项目及机构汇聚到不同的欧洲地点，定期交流最佳实践和研发信息。从 2006 年开始，CERN 与 ESTRO 和其他参与 HT 的合作伙伴合作，继续协调 ENLIGHT。在欧盟第七框架计划（2008-2014 年）中启动了重大项目，用于研发和跨国准入（ULICE、ENVISION）以及教育和培训网络（玛丽·居里 ITN：PARTNER、ENTERVISION）。这些项目为加强强子治疗领域发挥了重要作用。随着 4 个欧洲碳离子和质子中心以及即将到来的众多欧洲质子治疗中心的启动，ENLIGHT 的未来范围将侧重于加强当前和发展中的欧洲粒子治疗研究、多学科教育和培训以及技术和生物学方面的一般研发，其方式是通过年会和持续的 CERN 支持。将继续与欧洲粒子治疗网络（EPTN）和其他类似网络合作。
